open access

Vol 4, No 3 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-05-22
Get Citation

The efficacy of Divascan® (iprazochrome) in the prevention and treatment of early diabetic retinopathy

Barbara Mirkiewicz-Sieradzka, Katarzyna Cyganek, Jacek Sieradzki
Diabetologia Praktyczna 2003;4(3):193-198.

open access

Vol 4, No 3 (2003): Practical Diabetology
Original articles (submitted)
Published online: 2003-05-22

Abstract

INTRODUCTION. The study was undertaken to assess the efficacy of Divascan® (iprazochrome) in the prevention of the development of diabetic retinopathy and treatment of its early variant in patients with diabetes type 2. The safety of the drug was analysed in patients receiving chronic treatment.
MATERIAL AND METHODS. The study population consisted of 25 patients (49 eyes) with diabetes type 2 and early non-proliferative retinopathy or without the symptoms of retinopathy by ophthalmoscopy and fundus colour photography. The study was conducted in the double-blind placebo-controlled manner. The drug was given orally in a dose of 5 mg 3 times a day. The duration of follow-up was 12 months. The therapeutic outcome was analysed on the following scale: +1 — improvement, 0 — stable, -1 — deterioration. Statistical analysis was performed using chi square and Mann-Whitney’s tests.
RESULTS. The mean value for the whole group was higher (according to the scale adopted) in the treatment group (0.17; SD = 0.48) as compared with the controls (0.12; SD = 0.44). The percent improvement was also higher in the treatment group. A separate analysis of patients with and without retinopathy revealed a higher percentage value in stable for the treatment group with retinopathy as compared with the controls. The eyes without retinopathy were found stable. Better results of the treatment were observed in women (mean for the treatment group 0.29; SD = 0.47, for the controls 0.17; SD = 0.41) as compared with men - in the treatment group - who were stable. Better results were also found in younger patients.
CONCLUSIONS
1. Divascan® (iprazochrome) may be useful in the treatment of early diabetic retinopathy in patients with type 2 diabetes.
2. In patients with diabetes type 2 without retinopathy Divascan® (iprazochrome) may prevent the development of retinopathy.
3. Divascan® (iprazochrome) is well tolerated drug and no side effects were observed in chronic treatment.

Abstract

INTRODUCTION. The study was undertaken to assess the efficacy of Divascan® (iprazochrome) in the prevention of the development of diabetic retinopathy and treatment of its early variant in patients with diabetes type 2. The safety of the drug was analysed in patients receiving chronic treatment.
MATERIAL AND METHODS. The study population consisted of 25 patients (49 eyes) with diabetes type 2 and early non-proliferative retinopathy or without the symptoms of retinopathy by ophthalmoscopy and fundus colour photography. The study was conducted in the double-blind placebo-controlled manner. The drug was given orally in a dose of 5 mg 3 times a day. The duration of follow-up was 12 months. The therapeutic outcome was analysed on the following scale: +1 — improvement, 0 — stable, -1 — deterioration. Statistical analysis was performed using chi square and Mann-Whitney’s tests.
RESULTS. The mean value for the whole group was higher (according to the scale adopted) in the treatment group (0.17; SD = 0.48) as compared with the controls (0.12; SD = 0.44). The percent improvement was also higher in the treatment group. A separate analysis of patients with and without retinopathy revealed a higher percentage value in stable for the treatment group with retinopathy as compared with the controls. The eyes without retinopathy were found stable. Better results of the treatment were observed in women (mean for the treatment group 0.29; SD = 0.47, for the controls 0.17; SD = 0.41) as compared with men - in the treatment group - who were stable. Better results were also found in younger patients.
CONCLUSIONS
1. Divascan® (iprazochrome) may be useful in the treatment of early diabetic retinopathy in patients with type 2 diabetes.
2. In patients with diabetes type 2 without retinopathy Divascan® (iprazochrome) may prevent the development of retinopathy.
3. Divascan® (iprazochrome) is well tolerated drug and no side effects were observed in chronic treatment.
Get Citation

Keywords

diabetic retinopathy; prevention; pharmacological treatment; Divascan (iprazochrome)

About this article
Title

The efficacy of Divascan® (iprazochrome) in the prevention and treatment of early diabetic retinopathy

Journal

Clinical Diabetology

Issue

Vol 4, No 3 (2003): Practical Diabetology

Pages

193-198

Published online

2003-05-22

Bibliographic record

Diabetologia Praktyczna 2003;4(3):193-198.

Keywords

diabetic retinopathy
prevention
pharmacological treatment
Divascan (iprazochrome)

Authors

Barbara Mirkiewicz-Sieradzka
Katarzyna Cyganek
Jacek Sieradzki

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl